Skip to main navigation Skip to search Skip to main content

Ropivacaine Use in Femoral Nerve Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)

    • Healthpoint Hospital

    Project: Clinical Trial

    Project Details

    Description

    The aim of this study is to determine the minimal effective ropivacaine concentration required to provide adequate analgesic femoral nerve block in 90% of patients (MEAC90).

    Layman's description

    - Before induction of GA, all patients will receive sciatic, obturator, lateral femoral cutaneous and femoral nerve blocks.

    - The femoral nerve block will be performed using 15ml of ropivacaine which concentration relied on the response of the previous patient.

    - Based on biased-coin design up-down sequential method: when a patient has a negative response, the next patient will receive a concentration 0.01% w/v higher. However if he has a positive response, the next patient will be randomized to receive either the same ropivacaine concentration or a concentration 0.01% w/v less.

    - Patients with pain free recovery will be considered to have positive response.

    - Patients' responses will be analyzed to calculate the MEAC90
    StatusFinished
    Effective start/end date1/05/2130/09/21

    Collaborative partners

    Keywords

    • Postoperative Complications
    • Pathologic Processes
    • Pain
    • Neurologic Manifestations
    • Postoperative Pain
    • Local Anesthetics
    • Anesthetics
    • Central Nervous System Depressants
    • Physiological Effects of Drugs
    • Sensory System Agents
    • Peripheral Nervous System Agents
    • Ropivacaine

    Fingerprint

    Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.